Status:
ACTIVE_NOT_RECRUITING
Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions:
DLBCL - Diffuse Large B Cell Lymphoma
Eligibility:
All Genders
18-99 years
Brief Summary
This study will ultimately aim at providing the scientific community with patient-reported health status data that will contribute facilitate decision-makings. Short- and long-term HRQoL and symptoms ...
Detailed Description
Quality of life assessment
Eligibility Criteria
Inclusion
- Patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL transformed by indolent lymphoma and mantle cell lymphoma.
- Scheduled to received CAR-T cell product.
- Having a baseline PRO assessment.
- Adult patients (≥ 18 years old).
- Written informed consent provided.
Exclusion
- Having any documented or psychiatric or neurological disorder which may interfere with self-reported HRQoL assessment.
- Not able to read and understand local language.
Key Trial Info
Start Date :
June 29 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 15 2026
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT06026644
Start Date
June 29 2022
End Date
April 15 2026
Last Update
July 25 2024
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Aou Di Bologna - Policlinico S. Orsola-malpighi - Uoc Ematologia
Bologna, Italy
2
Asst Degli Spedali Civili Di Brescia - Ssvd Centro Trapianti Midollo Per Adulti - Cattedra Di Ematologia
Brescia, Italy
3
AOU Careggi - SOD terapie cellulari e Medicina Trasfusionale
Florence, Italy
4
Irccs Aou San Martino - Genova - Uo Ematologia E Trapianti
Genova, Italy